Squibb approved to analyze Zydus' product in ongoing India patent dispute
US pharmaceutical giant Squibb has been authorized by India’s top court to conduct technical "product-to-claim mapping" of Zydus’ anti-cancer biosimilar. The Supreme Court of India's directive of physical comparison will determine if...To view the full article, register now.
Already a subscriber? Click here to view full article